Skip to main navigation menu Skip to main content Skip to site footer

No. 3 (2024)

ORIRGINAL RESEARCH

Clinical Experience of Mioreol® Use in the Treatment of Dementia Caused by Alzheimer’s Disease

Published 2024-09-30

  • Ya.B. Fedorova
    • ,
  • I.V. Kolykhalov
    • ,
  • S.I. Gavrilova
    • ,
  • E.V. Ponomareva
    • ,
  • N.D. Selezneva

Ya.B. Fedorova
Mental Health Research Center

I.V. Kolykhalov
Mental Health Research Center

S.I. Gavrilova
Mental Health Research Center

E.V. Ponomareva
Mental Health Research Center

N.D. Selezneva
Mental Health Research Center

Abstract

The relevance of the study is the urgent need to find new treatment options for Alzheimer’s disease (AD) to reduce cognitive deficits and neuropsychiatric symptoms. The aim of this study was to analyze the efficacy and safety of Mioreol® in patients with moderate to moderate-severe dementia due to AD in a non-interventional observational programme.

Materials and methods. The study was conducted in 30 patients with moderate and moderate-severe AD aged from 61 to 90 years (median age 73.5 [68.00; 78.00]). Nineteen patients had moderate dementia and 11 had moderate — severe dementia. The therapeutic dose of Mioreol® was 10 mg donepezil + 20 mg memantine, taken orally once a day at the same time, independent of meals. The duration of study was 24 weeks. The effects of the drug were assessed using the MMSE, ADAS-Cog, NPI and CGI scales at baseline and by the end of 12 and 24 weeks of treatment.

Results. The use of Mioreol® in a six-month therapy of AD patients with moderate and moderate-severe dementia showed a positive effect (CGI-C scale) in 54.2 % of the total number of AD patients; to note, an improvement was observed in 80 % of patients with moderate stage of dementia caused by AD. During the Mioreol® therapy cognitive function, psychotic and behavioral symptoms significantly improved. In majority of patients with moderate-severe AD, cognitive was observed in, severity of behavioral and psychotic symptoms did not change significantly compared to baseline.

Conclusion. Fixed-dose combination therapy with Mioreol® (donepezil10 mg/memantine 20 mg) is effective and well tolerated in patients with moderate and moderate-severe AD. The use in patients with moderate stage of dementia caused by AD is more effective. The use of Mioreol® with fixed doses of doneperil and memantine is more convenient than taking two separate drugs twice a day, which improves adhence to therapy for these patients.

Keywords

Alzheimer’s disease, cholinesterase inhibitor, donepezil, fixed-dose combination, memantine, Mioreol®

PDF (Русский)

References

  1. 2024 Alzheimer’s disease facts and figures // Alzheimers Dement. – 2024. – Vol. 20 (5). – Pp. 3708-3821. – https://doi.org/10.1002/alz.13809
  2. Cummings J., Zhou Y., Lee G., Zhong K., Fonseca J., Cheng F. Alzheimer’s disease drug development pipeline: 2024 // Alzheimers Dement (N Y). – 2024. – Vol. 10 (2). – e12465.– https://doi.org/10.1002/trc2.12465
  3. Farlow M., Anand R., Messina J. Jr., Hartman R., Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease // EurNeurol. – 2000. – Vol. 44 (4). – Pp. 236–241. – https://doi.org/10.1159/000008243
  4. Gauthier S., Molinuevo J.L. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease // Alzheimers Dement. – 2013. – Vol. 9 (3). – Рp. 326–331. – https://doi.org/10.1016/j.jalz.2011.11.005
  5. Atri A., Molinuevo J.L., Lemming O., Wirth Y., Pulte I., Wilkinson D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy // AlzheimersResTher. – 2013. – Vol. 5 (1). – Art. 6. – https://doi.org/10.1186/alzrt160
  6. Matsunaga S., Kishi T., Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease: a systematic review and meta-analysis // Int J Neuropsychopharmacol. – 2014. – Vol. 18 (5). – pyu115. – https://doi.org/10.1093/ijnp/pyu115
  7. Farrimond L.E., Roberts E., McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review // BMJ Open. – 2012. – Vol. 2 (3). – e000917. – https://doi.org/10.1136/bmjopen-2012-000917
  8. National Institute for Clinical Excellence (NICE) Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease. NICE Technology Appraisal Guidance 217 (Review of NICE Technology Appraisal Guidance 111) // National Institute for Clinical Excellence. – 2011. – Available at: http://publications.nice.org.uk/donepezil-galantamine-rivastigmine-and-memantinefor-the-treatment-of-alzheimers-disease-ta217/guidance (accessed March 23, 2024).
  9. Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) capsules. US Food and Drug Administration. – 2014. – Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206439Orig1s000TOC.cfm (accessed May 17, 2024).
  10. Deardorff W.J., Grossberg G.T. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease // Drug Des Devel Ther. – 2016. – Vol. 10. – Рp. 3267–3279. – https://doi.org/10.2147/DDDT.S86463
  11. Колыхалов И.В., Мхитарян Э.А., Федорова Я.Б., Пономарева Е.В., Селезнева Н.Д., Чердак М.А., Дудченко Н.Г., Сейфединова А.Б., Исаев Р.И., Гаврилова С.И., Ткачева О.Н. Российский опыт применения комбинации фиксированных доз донепезила и мемантина в терапии болезни Альцгеймера в рамках наблюдательной неинтервенционной многоцентровой программы // Журнал неврологии и психиатрии имени С.С. Корсакова. – 2023 – № 12 (123). – С. 69-75. – https://doi.org/10.17116/jnevro202312312169
  12. Tang B.C., Wang Y.T., Ren J. Basic information about memantine and its treatment of Alzheimer’s disease and other clinical applications // Ibrain. – 2023. – Vol. 9 (3). – Рp. 340–348. – https://doi.org/10.1002/ibra.12098
  13. Nagata T., Shinagawa S., Nakajima S., Noda Y., Mimura M. Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease // Expert OpinPharmacother. – 2022. – Vol. 23 (6). – Рp. 727–737. – https://doi.org/10.1080/14656566.2022.2042514
  14. Wolff J.L., Starfield B., Anderson G. Prevalence, Expenditures, and Complications of Multiple Chronic Conditions in the Elderly // Arch Intern Med. – 2002 – Vol. 162 (20). – Pp. 2269–2276. – https://doi.org/10.1001/archinte.162.20.2269
  15. Calvó-Perxas L., Turró-Garriga O., Vilalta-Franch J., Lozano-Gallego M., de Eugenio R,. Márquez F., Carmona O., Gich J., Manzano A., Viñas M., Roig A.M., Garre-Olmo J. Registry of Dementias of Girona Study Group (ReDeGi Study Group). Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer›s Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona // Drugs Aging. – 2017. – Vol. 34 (4). – Рp. 303–310. –https://doi.org/10.1007/s40266-017-0446-x
  16. Touchon J., Lachaine J., Beauchemin C., Granghaud A., Rive B., Bineau S. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer›s disease to nursing homes: cost-effectiveness analysis in France // Eur J Health Econ. – 2014. – Vol. 15 (8). – Рp. 791–800. – https://doi.org/10.1007/s10198-013-0523-y

Downloads

Download data is not yet available.